MARIMED INC. shareholders approved Advisory approval of the appointment of M&K CPAs PLLC as the Company's independent auditors for fiscal year 2026. at the 2026-06-04 meeting.
“VOTES FOR AGAINST ABSTAIN/WITHHELD 229,335,138 15,550,371 574,116”
MARIMED INC. — fact timeline
Source-grounded facts extracted from MARIMED INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MARIMED INC. shareholders approved Election of four directors to serve until the next annual meeting or until successors are elected and qualified. at the 2026-06-04 meeting.
“VOTES NAME FOR WITHHELD BROKER NON-VOTE Jon R. Levine 111,339,122 14,355,396 119,765,107 Edward Gildea 110,868,950 14,825,568 119,765,107 David Allen 110,854,282 14,840,236 119,765,107 Eva Selhub, M.D. 111,358,888 14,335,630 119,765,107”
MARIMED INC. reported financial results for first quarter ended March 31, 2026.
“On May 13, 2026, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three-month period ended March 31, 2026.”
MARIMED INC. reported fourth quarter and year ended December 31, 2025 results: revenue $159.8 million, net income GAAP Net loss $ (14.5).
“Adjusted EBITDA for the sixth consecutive year, reflecting the strength of its branded product portfolio and disciplined operational execution. 2025 Highlights • Revenue of $159.8 million • Sixth consecutive year of positive Adjusted EBITDA • Wholesale revenue increased 11% • Distribution expanded to 85% of dispensaries in core markets • Betty’s Eddies ranked #1”
MARIMED INC. issued 26,900,000 shares of New Series B Preferred Stock of preferred stock to Navy Capital Green International, Ltd. and its affiliates for extinguishment of Series B Obligation and cancellation of prior Series B Preferred Stock.
“On February 24, 2026, in connection with the Loan Restructuring Transaction described in Item 1.01 above, the Company issued 26,900,000 shares of New Series B Preferred Stock to Navy.”
MARIMED INC.: Filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock (effective 2026-02-26).
“On February 26, 2026, in connection with the Loan Restructuring Transaction, the Company filed a Second Amended and Restated Certificate of Designation to designate the rights and preferences of the New Series B Preferred Stock with the Secretary of State of Delaware.”
MARIMED INC. incurred senior notes of principal amount of $6,000,000 with Navy Capital Green International, Ltd. and its affiliates at 10.0% per annum maturing March 1, 2031.
“the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum ("Note #1") and the other in the principal amount of $6,000,000, due March 1, 2031, accruing interest at a rate of 10.0% per annum (subject to reduction to 8% if Note #1 is paid in full within six (6) months of February 24, 2026) ("Note #2" collectively with Note #1, the "New Notes")”
MARIMED INC. incurred senior notes of aggregate principal amount of $8,000,000 with Navy Capital Green International, Ltd. and its affiliates at 8.0% per annum maturing March 1, 2028.
“the Company issued to Navy (i) two new promissory notes in the aggregate principal amount of $8,000,000, one in the principal amount of $2,000,000, due March 1, 2028, accruing interest at a rate of 8.0% per annum ("Note #1")”
MARIMED INC. entered into Restructuring and Exchange Agreement with Navy Capital Green International, Ltd. valued at $8,000,000 (effective 2026-02-24).
“On February 24, 2026, the Company and Navy entered into a Restructuring and Exchange Agreement (the “Restructuring and Exchange Agreement”) to address and restructure the Series B Obligation”
Mario Pinho was appointed as Chief Financial Officer at MARIMED INC..
“Effective August 9, 2024, MariMed Inc. (the “Company”) appointed Mario Pinho as the Company's Chief Financial Officer to replace Jon Levine, the Company's Interim Chief Financial Officer.”
MARIMED INC. reported the first quarter ended March 31, 2024 results: revenue $ 37.9, net income $ (1.3).
“1 The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts): Three months ended March 31, 2024 2023 Revenue $ 37.9 $ 34.4 GAAP Gross margin 43 % 45 % Non-GAAP Gross margin 44 % 46 % GAAP Net loss $ (1.3) $ (0.7) Non-GAAP Net (loss) income $ (0.6) $ 0.3 Non-GAAP Adjusted EBITDA $ 4.7 $ 7.1”
MARIMED INC. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 6, 2024, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing its financial results for the three months and year ended December 31, 2023.”
MARIMED INC. incurred loan of $58.7 million with Needham Bank at Initial five-years: 8.43%. Interest rate resets after five-years to the FHLB Rat maturing Ten years.
“On November 16, 2023, Mari Holdings MD LLC, Hartwell Realty Holdings LLC, Kind Therapeutics USA, LLC, ARL Healthcare Inc., and MariMed Advisors, Inc., each a wholly-owned direct or indirect subsidiary of the Registrant (collectively, the “ Borrowers ”) entered into a Loan Agreement (the “ Loan Agreement ”), by and among Borrowers, and Needham Bank, a Massachusetts co-operative bank (the “ Lender ”) pursuant to which the Lender loaned to the Borrowers an aggregate principal amount of $58.7 million (the “ Loan Transaction ”).”
MARIMED INC. entered into Loan Agreement with Needham Bank valued at $58.7 million (effective 2023-11-16).
“On November 16, 2023, Mari Holdings MD LLC, Hartwell Realty Holdings LLC, Kind Therapeutics USA, LLC, ARL Healthcare Inc., and MariMed Advisors, Inc., each a wholly-owned direct or indirect subsidiary of the Registrant (collectively, the “ Borrowers ”) entered into a Loan Agreement (the “ Loan Agreement ”), by and among Borrowers, and Needham Bank, a Massachusetts co-operative bank (the “ Lender ”) pursuant to which the Lender loaned to the Borrowers an aggregate principal amount of $58.7 million (the “ Loan Transaction ”).”
MARIMED INC. reported nine months ended September 30, 2023 results: revenue $ 109.7, net income $ (5.9).
“Three months ended September 30, Nine months ended September 30, 2023 2022 2023 2022 Revenue $ 38.8 $ 33.9 $ 109.7 $ 98.2 GAAP Gross margin 43 % 48 % 44 % 49 % Non-GAAP Gross margin 45 % 48 % 45 % 49 % GAAP Net (loss) income $ (4.3) $ 2.7 $ (5.9) $ 8.9 Non-GAAP Net (loss) income $ (3.1) $ 4.7 $ (2.2) $ 17.0 Non-GAAP Adjusted EBITDA $ 6.1 $ 8.6 $ 19.4 $ 27.9 Non-GAAP Adjusted EBITDA margin 16 % 25 % 18 % 28 %”
MARIMED INC. reported three months ended September 30, 2023 results: revenue $ 38.8, net income $ (4.3).
“Three months ended September 30, Nine months ended September 30, 2023 2022 2023 2022 Revenue $ 38.8 $ 33.9 $ 109.7 $ 98.2 GAAP Gross margin 43 % 48 % 44 % 49 % Non-GAAP Gross margin 45 % 48 % 45 % 49 % GAAP Net (loss) income $ (4.3) $ 2.7 $ (5.9) $ 8.9 Non-GAAP Net (loss) income $ (3.1) $ 4.7 $ (2.2) $ 17.0 Non-GAAP Adjusted EBITDA $ 6.1 $ 8.6 $ 19.4 $ 27.9 Non-GAAP Adjusted EBITDA margin 16 % 25 % 18 % 28 %”
Jon R. Levine was appointed as Interim Chief Financial Officer at MARIMED INC..
“The Board of Directors has appointed Jon R. Levine, the Company's President and Chief Executive Officer, as the Company's Interim Chief Financial Officer”
Susan M. Villare resigned as Chief Financial Officer at MARIMED INC..
“Effective October 31, 2023 Susan M. Villare resigned as the Chief Financial Officer of MariMed Inc.”
MARIMED INC. shareholders approved Advisory Approval of Auditors at the 2023-06-08 meeting.
“approved, on an advisory basis, the appointment of M&K CPAs PLLC as the Company's independent auditors for the 2023 fiscal year the ("Advisory Approval of Auditors")”
MARIMED INC. shareholders approved Election of Directors at the 2023-06-08 meeting.
“re-elected the Company's five directors to serve until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified (the "Election of Directors")”
MARIMED INC. reported the first quarter ended March 31, 2023 results: revenue $34.4, net income $(0.7).
“Financial Highlights 1 The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts): Three months ended March 31, 2023 2022 Revenue $ 34.4 $ 31.3 GAAP Gross margin 45 % 54 % Non-GAAP Gross margin 46 % 54 % GAAP Net (loss) income $ (0.7) $ 4.2 Non-GAAP Net income $ 0.3 $ 6.9 Non-GAAP Adjusted EBITDA $ 7.1 $ 10.4 Non-GAAP Adjusted EBITDA margin 21 % 33 %”
Kathleen Tucker was appointed as Board of Directors at MARIMED INC..
“Effective April 17, 2023, Kathleen Tucker was appointed to the Board of Directors (the “Board”) of MariMed Inc. (the “Company”).”
MARIMED INC.: Amended Bylaws to revise powers and duties of Chairman, CEO, and President (effective 2023-02-28).
“On February 28, 2023, the Board of Directors of MariMed Inc. (the “ Corporation ”), in conjunction with the appointment of Edward Gildea as Chairman of the Board and Jon R. Levine as Chief Executive Officer of the Corporation, authorized, approved and adopted an amendment the Corporation’s Bylaws (the “ Bylaws ”), to revise the powers and duties of the Corporation’s Chairman of the Board, Chief Executive Officer and President as set forth in Sections 4 and 5 of Article IV of the Bylaws, as amended.”
MARIMED INC. reported year ended December 31, 2022 results: revenue $134.0, net income $13.6.
“2022 and 2021 (in millions, except percentage amounts): Financial Highlights 1 Three months ended Year ended December 31, December 31, 2022 2021 2022 2021 Revenue $ 35.8 $ 31.0 $ 134.0 $ 121.5 GAAP Gross margin 44 % 50 % 48 % 55 % Non-GAAP Gross margin 45 % 50 % 48 % 55 % GAAP Net income (loss) $ 4.8 $ (6.4) $ 13.6 $ 7.6 Non-GAAP Net income $ 5.2 $ 0.1 $ 22.2 $”
MARIMED INC. reported three months ended December 31, 2022 results: revenue $35.8, net income $4.8.
“December 31, 2022 and 2021 (in millions, except percentage amounts): Financial Highlights 1 Three months ended Year ended December 31, December 31, 2022 2021 2022 2021 Revenue $ 35.8 $ 31.0 $ 134.0 $ 121.5 GAAP Gross margin 44 % 50 % 48 % 55 % Non-GAAP Gross margin 45 % 50 % 48 % 55 % GAAP Net income (loss) $ 4.8 $ (6.4) $ 13.6 $ 7.6 Non-GAAP Net income $ 5.2”
MARIMED INC. incurred credit facility of $35 million in principal borrowings; $30 million initially funded with Chicago Atlantic Admin, LLC at floating annual interest rate equal to the prime rate then in effect plus 5.75% maturing January 24, 2026, subject to extension to January 24, 2028.
“Kind acquisition in April 2022. The remaining balance, if any, will be used to fund acquisitions. Principal, Security, Interest and Prepayments The Credit Agreement provides for $35 million in principal borrowings at the Borrowers’ option in the aggregate and further provides the Borrowers with the right, subject to customary conditions, to request an additional”
MARIMED INC. entered into Loan and Security Agreement with Chicago Atlantic Admin, LLC valued at $35 million credit facility with $30 million funded at closing and up to $5 million additional drawd (effective 2023-01-24).
“On January 24, 2023, MariMed Inc., a Delaware corporation (the “ Company ”), entered into a Loan and Security Agreement (the “ Credit Agreement ”), by and among the Company, subsidiaries of the Company from time-to-time party thereto (together with the Company, collectively, the “ Borrowers ”), lenders from time-to-time party thereto (the “ Lenders ”), and Chicago Atlantic Admin, LLC, a Delaware limited liability company (“ Chicago Atlantic ”), as administrative agent for the Lenders. Proceeds from the Credit Agreement are designated to complete the build-out of a new cultivation and processing facility in Illinois, complete the buildout of a new processing kitchen in Missouri, expand existing cultivation and processing facilities in Massachusetts and Maryland, fund certain capital expenditures, and to repay in full the Kind Therapeutics seller notes incurred in connection with the Kind acquisition in April 2022. The remaining balance, if any, will be used to fund acquisitions. Princip”
MARIMED INC. reported third quarter ended September 30, 2022 results: revenue $33.9, net income $2.7.
“financial highlights for the three months ended September 30, 2022 and 2021 (in millions, except percentage amounts): Three months ended September 30, 2022 2021 Revenue $ 33.9 $ 33.2 Gross margin 48 % 55 % GAAP Net income $ 2.7 $ 2.1 Non-GAAP Adjusted EBITDA $ 8.6 $ 12.6 Non-GAAP Adjusted EBITDA margin 25 % 38 % 1 See the reconciliations of”
MARIMED INC. shareholders approved Advisory approval of Auditors at the 2022-10-27 meeting.
“2. Advisory approval of Auditors: VOTES FOR AGAINST ABSTAIN 227,091,546 537,750 1,245,158”
MARIMED INC. shareholders approved Election of Directors at the 2022-10-27 meeting.
“1. The Election of Directors: VOTES For WITHHELD BROKER NON-VOTE Robert Fireman 138,918,236 1,753,185 88,203,033 Jon R. Levine 138,002,182 2,669,239 88,203,033 David Allen 137,829,140 2,842,281 88,203,033 Edward Gildea 137,817,074 2,854,347 88,203,033 Eva Selhub, M.D 139,043,020 1,628,401 88,203,033”
Robert Fireman changed role as President at MARIMED INC..
“Effective September 7, 2022 (the “ Effective Date ”), MariMed Inc. (the “ Company ”) promoted Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the “ Promotion ”).”
Jon Levine changed role as President at MARIMED INC..
“Effective September 7, 2022 (the “ Effective Date ”), MariMed Inc. (the “ Company ”) promoted Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the “ Promotion ”).”
Jon Levine changed role as Chief Administrative Officer at MARIMED INC..
“Jon Levine, the Chief Financial Officer of the Company at the time of her appointment, was promoted to the position of Chief Administrative Officer of the Company.”
Susan M. Villare was appointed as Chief Financial Officer at MARIMED INC..
“the Company appointed Susan M. Villare as the Company’s Chief Financial Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.